51
|
He Y, Xu LL, Feng FE, Wang QM, Zhu XL, Wang CC, Zhang JM, Fu HX, Xu LP, Liu KY, Huang XJ, Zhang XH. Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia. Br J Haematol 2018; 180:395-411. [PMID: 29327472 DOI: 10.1111/bjh.15034] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Accepted: 09/19/2017] [Indexed: 12/27/2022]
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease. Mesenchymal stem cells (MSCs) play important roles in the physiology and homeostasis of the haematopoietic system, including supporting megakaryocytic differentiation from CD34+ haematopoietic progenitor cells. Tumour necrosis factor alpha-induced protein 3 (TNFAIP3, also termed A20) plays a key role in terminating NF-κB signalling. Human genetic studies showed that the polymorphisms of the TNFAIP3 gene may contribute to ITP susceptibility. In this study, we showed a significant decrease in TNFAIP3 and increase in NF-κB/SMAD7 in ITP-MSCs. In co-cultures with CD34+ cells, NF-κB was overexpressed in MSCs from healthy controls (HC-MSCs) after transfection with NFKBIA (IκB)-specific short hairpin (sh)RNAs, resulting in MSC deficiency and a reduction in megakaryocytic differentiation and thrombopoiesis. Knockdown of TNFAIP3 expression using TNFAIP3-specific shRNAs in HC-MSCs affected megakaryocytopoiesis. However, IKBKB knockdown corrected megakaryocytopoiesis inhibition in the ITP-MSCs by decreasing NF-κB expression. Amplified TNFAIP3 expression in ITP-MSCs by TNFAIP3 cDNA can facilitate megakaryocyte differentiation. shRNA-mediated knockdown of SMAD7 expression rescued the impaired MSC function in ITP patients. Therefore, we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-κB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34+ cells was impaired.
Collapse
Affiliation(s)
- Yun He
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.,Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.,Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Lin-Lin Xu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Fei-Er Feng
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Qian-Ming Wang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Xiao-Lu Zhu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Chen-Cong Wang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Jia-Min Zhang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Hai-Xia Fu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Lan-Ping Xu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.,Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.,Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Kai-Yan Liu
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.,Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.,Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Xiao-Jun Huang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.,Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.,Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| | - Xiao-Hui Zhang
- Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.,Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.,Collaborative Innovation Centre of Haematology, Peking University, Beijing, China
| |
Collapse
|
52
|
Xu LL, Fu HX, Zhang JM, Feng FE, Wang QM, Zhu XL, Xue J, Wang CC, Chen Q, Liu X, Wang YZ, Qin YZ, Kong Y, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells Dev 2017; 26:1648-1661. [PMID: 28946811 DOI: 10.1089/scd.2017.0078] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease in which dendritic cells (DCs) play a crucial role in the breakdown of self-tolerance. Studies have identified the function of mesenchymal stem cells (MSCs) in promoting the development of regulatory DCs (regDCs). Our previous work revealed that MSCs in ITP exerted senescence, apoptosis, and impaired immunosuppressive effects on T and B cells. However, it is unclear whether the effects of MSCs on regDC induction are altered in ITP. Our data demonstrated that MSCs in ITP were impaired in inhibiting CD1a+ DC and CD14+ DC differentiation from CD34+ hematopoietic progenitor cells (CD34+ HPCs). DCs differentiated with MSCs in ITP exhibited an increased expression of costimulatory molecules CD80/CD86 and secretion of proinflammatory interleukin-12 (IL-12). Accordingly, the tolerogenic characteristics were deficient in DCs induced by MSCs in ITP. DCs differentiated with MSCs in ITP exhibited an impaired ability to inhibit CD3+ T cell proliferation, to suppress T helper (Th)1 cell differentiation, and to induce anergic and regulatory T cells (Tregs). The expression of Notch signaling components was measured in MSCs in ITP. Reduced expression of the ligand Jagged-1, the receptor Notch-1 intracellular domain (NICD-1), and the target gene Hes-1 was identified in MSCs in ITP. The addition of biologically active Jagged-1 to CD34+ HPCs was observed to promote regDC differentiation. When cultured on Jagged-1-coated plates, MSCs in ITP showed an enhancement of the Notch-1 pathway activation, Jagged-1 expression, and the function in inducing regDCs. Pretreatment with all-trans retinoic acid (ATRA) was found to partially restore the capacity of MSCs in both ITP patients and healthy controls in inducing CD34+-derived regDCs. Our data elucidated that MSCs in ITP were impaired in inducing CD34+-regDCs, associated with the Notch-1/Jagged-1 signaling pathway. ATRA could partially correct the impairment of MSCs, suggesting that ATRA could serve as a potential therapeutic alternative for ITP.
Collapse
Affiliation(s)
- Lin-Lin Xu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Hai-Xia Fu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Jia-Min Zhang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Fei-Er Feng
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Qian-Ming Wang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Xiao-Lu Zhu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Jing Xue
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Chen-Cong Wang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Qi Chen
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Xiao Liu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Ya-Zhe Wang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Ya-Zhen Qin
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Yuan Kong
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Ying-Jun Chang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Lan-Ping Xu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Kai-Yan Liu
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Xiao-Jun Huang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| | - Xiao-Hui Zhang
- 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing, China .,2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, China .,3 Collaborative Innovation Center of Hematology, Peking University , Beijing, China
| |
Collapse
|